Prothena Corporation plc (PRTA)

Currency in USD
21.530
0.000(0.00%)
Closed·
Showing Prothena historical data. For real-time data please try another search
Day's Range
21.08021.890
52 wk Range
0.00021.890
Key Statistics
Prev. Close
21.53
Open
21.7
Day's Range
21.08-21.89
52 wk Range
0-0
Volume
-
Average Volume (3m)
219.24K
1-Year Change
-2.4%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Prothena Corporation plc News & Analysis

Show more

Prothena Corporation plc Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Industry
-
Sector
-
Employees
163

Prothena Corporation plc SWOT Analysis


Pipeline Potential
Explore Prothena's diverse portfolio targeting neurodegenerative and rare diseases, with key programs in AL amyloidosis, Alzheimer's, and Parkinson's
Financial Health
Delve into Prothena's robust cash position and controlled burn rate, supporting its ambitious clinical development programs
Market Opportunity
Learn about the substantial market potential for Prothena's lead candidates, with projected peak sales for birtamimab reaching $1.4 billion by 2033
Analyst Outlook
Discover varied analyst perspectives, with price targets ranging from $18 to $83, reflecting the high-risk, high-reward nature of Prothena's pipeline
Read full SWOT analysis

Analyst Ratings

4 Buy
3 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-1.12 / --
Revenue / Forecast
2.83M / --
EPS Revisions
Last 90 days

PRTA Income Statement

People Also Watch

16.75
SRPT
-2.05%
5.262
NEXII
+0.34%
20.72
URGN
+4.23%
18.70
BEAM
-2.20%
25.89
CNC
-1.22%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.